X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2263) 2263
Publication (104) 104
Book Review (15) 15
Magazine Article (10) 10
Book / eBook (4) 4
Book Chapter (2) 2
Newsletter (2) 2
Newspaper Article (2) 2
Trade Publication Article (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2033) 2033
alopecia - chemically induced (1842) 1842
female (1499) 1499
male (1078) 1078
adult (1027) 1027
middle aged (925) 925
aged (642) 642
index medicus (402) 402
alopecia (380) 380
antineoplastic agents - adverse effects (362) 362
oncology (344) 344
animals (312) 312
dermatology (307) 307
antineoplastic combined chemotherapy protocols - adverse effects (276) 276
antineoplastic combined chemotherapy protocols - therapeutic use (263) 263
nausea - chemically induced (262) 262
chemotherapy (261) 261
breast neoplasms - drug therapy (256) 256
drug administration schedule (233) 233
leukopenia - chemically induced (231) 231
adolescent (228) 228
alopecia - prevention & control (208) 208
treatment outcome (193) 193
vomiting - chemically induced (183) 183
cancer (176) 176
neoplasms - drug therapy (175) 175
baldness (173) 173
alopecia - drug therapy (170) 170
doxorubicin - adverse effects (169) 169
child (152) 152
doxorubicin - administration & dosage (146) 146
hair loss (139) 139
neutropenia - chemically induced (137) 137
mice (128) 128
antineoplastic agents - therapeutic use (127) 127
time factors (127) 127
cyclophosphamide - adverse effects (126) 126
lung neoplasms - drug therapy (122) 122
drug evaluation (117) 117
pharmacology & pharmacy (113) 113
rats (113) 113
alopecia - pathology (110) 110
drug eruptions - etiology (110) 110
thrombocytopenia - chemically induced (110) 110
dose-response relationship, drug (107) 107
follow-up studies (106) 106
scalp (105) 105
therapy (101) 101
cyclophosphamide - administration & dosage (100) 100
drug therapy, combination (99) 99
paclitaxel - administration & dosage (99) 99
paclitaxel - adverse effects (98) 98
hair - drug effects (97) 97
hair (96) 96
cisplatin - administration & dosage (94) 94
remission induction (94) 94
aged, 80 and over (92) 92
child, preschool (89) 89
breast cancer (86) 86
care and treatment (86) 86
cyclophosphamide (86) 86
antineoplastic agents, phytogenic - adverse effects (83) 83
hair - growth & development (83) 83
infusions, intravenous (83) 83
medicine, general & internal (82) 82
skin (82) 82
young adult (82) 82
alopecia areata - chemically induced (81) 81
skin diseases - chemically induced (81) 81
prospective studies (80) 80
stomatitis - chemically induced (79) 79
diarrhea - chemically induced (77) 77
breast neoplasms - pathology (76) 76
doxorubicin - therapeutic use (74) 74
quality of life (74) 74
survival rate (74) 74
fluorouracil - administration & dosage (73) 73
doxorubicin (72) 72
administration, topical (71) 71
clinical trials as topic (70) 70
alopecia - psychology (69) 69
antineoplastic agents, phytogenic - administration & dosage (69) 69
administration, oral (68) 68
risk factors (68) 68
adenocarcinoma - drug therapy (67) 67
alopecia - diagnosis (67) 67
chemotherapy-induced alopecia (67) 67
cyclophosphamide - therapeutic use (67) 67
alopecia areata - drug therapy (66) 66
cisplatin - adverse effects (66) 66
dermatology & venereal diseases (65) 65
medicine & public health (65) 65
pregnancy (65) 65
neoplasm metastasis (64) 64
prevention (64) 64
antineoplastic agents - administration & dosage (62) 62
neoplasm staging (62) 62
research (62) 62
complications and side effects (60) 60
finasteride - adverse effects (60) 60
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1841) 1841
German (133) 133
Japanese (115) 115
French (65) 65
Spanish (23) 23
Chinese (22) 22
Russian (22) 22
Italian (21) 21
Polish (12) 12
Hungarian (5) 5
Swedish (5) 5
Dutch (3) 3
Hebrew (3) 3
Portuguese (3) 3
Czech (2) 2
Croatian (1) 1
Finnish (1) 1
Norwegian (1) 1
Romanian (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CARCINOGENESIS, ISSN 0143-3334, 12/2002, Volume 23, Issue 12, pp. 2103 - 2109
1,25-Dihydroxyvitamin D-3 (1,25D(3)) is the biologically active form of vitamin D3 that interacts with the nuclear vitamin D3 receptor (VDR) to modulate gene... 
TUMOR PROMOTION | INHIBITION | ONCOLOGY | HAIRLESS GENE | TARGETED ABLATION | ORNITHINE DECARBOXYLASE | MALIGNANT-MELANOMA | KNOCKOUT MICE | ALOPECIA | ATRICHIA | TRANSGENIC MICE
Journal Article
Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 19, pp. 2944 - 2952
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2017, Volume 146, Issue 2, pp. 386 - 391
Abstract Objectives Women with ovarian cancer can have long overall survival and goals of treatment change over time from cure to remission to stable disease.... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | Peripheral Nervous System Diseases - chemically induced | Diarrhea - psychology | Nausea - chemically induced | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Fatigue - chemically induced | Pain - chemically induced | Diarrhea - chemically induced | Arthralgia - chemically induced | Gastroesophageal Reflux - chemically induced | Nausea - psychology | Alopecia - psychology | Young Adult | Constipation - psychology | Patient Care Planning | Sexual Dysfunction, Physiological - psychology | Antineoplastic Agents - adverse effects | Adult | Female | Surveys and Questionnaires | Neoplasm Recurrence, Local - psychology | Survivors - psychology | Gastroesophageal Reflux - psychology | Ovarian Neoplasms - drug therapy | Arthralgia - psychology | Ovarian Neoplasms - psychology | Memory Disorders - psychology | Attitude to Health | Peripheral Nervous System Diseases - psychology | Fatigue - psychology | Sexual Dysfunction, Physiological - chemically induced | Drug-Related Side Effects and Adverse Reactions - etiology | Hospitalization | Remission Induction | Constipation - chemically induced | Vomiting - chemically induced | Pain - psychology | Adolescent | Vomiting - psychology | Quality of Life | Alopecia - chemically induced | Aged | Neoplasm Staging | Drug-Related Side Effects and Adverse Reactions - psychology | Memory Disorders - chemically induced | Complications and side effects | Ovarian cancer | Index Medicus
Journal Article
Journal Article
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 06/2017, Volume 123, Issue 12, pp. 2294 - 2302
BACKGROUND In a placebo‐controlled, randomized phase 2 trial (ClinicalTrials.gov identifier NCT01900743), regorafenib improved progression‐free survival (PFS)... 
quality‐adjusted time without symptoms of progression or toxicity (Q‐TWiST) | quality‐adjusted survival | regorafenib | placebo | metastatic soft‐tissue sarcoma | quality-adjusted survival | quality-adjusted time without symptoms of progression or toxicity (Q-TWiST) | metastatic soft-tissue sarcoma | PAZOPANIB | ONCOLOGY | PALETTE | DOUBLE-BLIND | PHASE-3 TRIAL | SUNITINIB | RENAL-CELL CARCINOMA | Humans | Middle Aged | Fecal Incontinence - chemically induced | Male | Antineoplastic Agents - therapeutic use | Hand-Foot Syndrome - etiology | Diarrhea - chemically induced | Hypertension - chemically induced | Female | Pyridines - therapeutic use | Severity of Illness Index | Double-Blind Method | Liposarcoma - drug therapy | Proportional Hazards Models | Phenylurea Compounds - therapeutic use | Treatment Outcome | Hospitalization | Sarcoma - drug therapy | Mucositis - chemically induced | Asthenia - chemically induced | Sarcoma, Synovial - drug therapy | Quality of Life | Alopecia - chemically induced | Anorexia - chemically induced | Leiomyosarcoma - drug therapy | Aged | Cancer patients | Care and treatment | Dosage and administration | Sarcoma | Doxorubicin | Sensitivity analysis | Adjustment | Toxicity | Quality | Stability analysis | Patients | Survival | Cancer | Index Medicus | Abridged Index Medicus | Original
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2014, Volume 32, Issue 32, pp. 3619 - 3625
Journal Article
British Journal of Dermatology, ISSN 0007-0963, 11/2009, Volume 161, Issue 5, pp. 1045 - 1051
Summary Background  The multitargeted kinase inhibitors sorafenib and sunitinib have improved treatment of solid tumours including renal cell carcinoma and... 
sunitinib | sorafenib | cutaneous adverse effects | Cutaneous adverse effects | Sunitinib | Sorafenib | THERAPY | HAIR | MANAGEMENT | KIT | IMATINIB | HAND-FOOT | FOOT SKIN REACTION | DERMATOLOGY | Niacinamide - analogs & derivatives | Humans | Middle Aged | Hand Dermatoses - chemically induced | Male | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Skin Diseases - pathology | Indoles - administration & dosage | Benzenesulfonates - adverse effects | Young Adult | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Aged, 80 and over | Pyrroles - adverse effects | Adult | Female | Retrospective Studies | Carcinoma, Renal Cell - drug therapy | Drug Eruptions - etiology | Skin Diseases - chemically induced | Pyridines - administration & dosage | Administration, Oral | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Gastrointestinal Stromal Tumors - drug therapy | Stomatitis - chemically induced | Foot Dermatoses - chemically induced | Alopecia - chemically induced | Aged | Kidney Neoplasms - drug therapy | Antimitotic agents | Complications and side effects | Liver cancer | Medical colleges | Care and treatment | Antineoplastic agents | Tumors | Index Medicus
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2015, Volume 72, Issue 2, pp. 221 - 236
The last decade has spawned an exciting new era of oncotherapy in dermatology, including the development of targeted therapies for metastatic melanoma and... 
Lambrolizumab | RAS | Ipilimumab | Panniculitis | Verrucal keratosis | Autoimmune dermopathies | PI3K-AKT-mTOR pathway | Seborrheic dermatitis | Temsirolimus | Pruritus | Dermatitis | Keratoacanthoma | Autoimmune adverse effects | Vitiligo | RAF inhibitors | Immunotherapy | Immune-related toxicities | mTOR inhibitor | B-RAF | Everolimus | PI3 kinase inhibitor | Squamous cell carcinoma | Dysgeusia | Selumetinib | Dual inhibitor | MEK inhibitors | Dabrafenib | Rapamycin | PD-1 inhibitor | Trametinib | Keratotic squamoproliferative lesion | Vemurafenib | AKT inhibitor | Loss of taste | Nivolumab | MAP kinase pathway | Hedgehog signaling pathway | Taste alteration | Vismodegib | Hair loss | Keratosis pilaris | pruritus | ADVANCED CANCER | lambrolizumab | nivolumab | dysgeusia | RENAL-CELL CARCINOMA | METASTATIC MELANOMA | ipilimumab | autoimmune adverse effects | AZD6244 ARRY-142886 | MAMMALIAN TARGET | vitiligo | TASTE PAPILLA DEVELOPMENT | BRAF INHIBITORS | vismodegib | hair loss | hedgehog signaling pathway | panniculitis | keratotic squamoproliferative lesion | keratoacanthoma | taste alteration | seborrheic dermatitis | VEMURAFENIB TREATMENT | DERMATOLOGY | trametinib | keratosis pilaris | everolimus | dermatitis | immunotherapy | autoimmune dermopathies | dabrafenib | verrucal keratosis | ADVANCED SOLID TUMORS | vemurafenib | selumetinib | loss of taste | temsirolimus | immune-related toxicities | dual inhibitor | rapamycin | squamous cell carcinoma | Drug Eruptions - etiology | Molecular Targeted Therapy - adverse effects | Skin Neoplasms - drug therapy | Photosensitivity Disorders - chemically induced | Humans | Carcinoma, Squamous Cell - chemically induced | Drug Eruptions - therapy | Skin Neoplasms - chemically induced | Photosensitivity Disorders - therapy | Immunotherapy - adverse effects | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Panniculitis - chemically induced | Signal Transduction - drug effects | Antineoplastic Agents - adverse effects | Drug Eruptions - diagnosis | Alopecia - chemically induced | Mitogen-Activated Protein Kinases - drug effects | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Index Medicus
Journal Article